FORGOT YOUR DETAILS?

Clinigen to acquire Link Healthcare

Tuesday, 22 September 2015 by

On 22 September 2015, Clinigen agreed to acquire Link Healthcare to grow the Group’s presence in the AAA region (Asia, Africa and Australasia) and strengthen its global leadership position in the ethical supply of licensed and unlicensed medicines. To read more | click here

Singapore/Sydney/Auckland/Greifswald: 27 Feb 2015 Specialist pharmaceutical and medical technologies business, LINK Healthcare (‘LINK’) is pleased to announce signing an exclusive agreement with RIEMSER Pharma GmbH (RIEMSER) of Berlin and Greifswald, Germany for the marketing and distribution of TEPADINA®, thiotepa infusion. TEPADINA® is indicated, in combination with other chemotherapy medicinal products as a conditioning treatment prior

Avexa Limited – Manufacture of ATC product for Named Patient Scheme completed Sydney/Pretoria/Singapore/Tokyo/Hong Kong/Auckland: 9th September 2014   Melbourne, Australia, Tuesday 9th September 2014: Australian biotechnology company Avexa Limited [ASX:AVX] today announced that the manufacture of ATC product intended for its Early Access / Named Patient Scheme has been completed successfully, on schedule and is

LINK Healthcare receives marketing approval for DermaScar®  DermaScar® (polysiloxane) is a scar reduction gel for the treatment of keloid and hypertrophic scarring.  Link’s newly formed Pharmacy Division expects more specialist products to follow Sydney/Pretoria/Singapore/Tokyo/Hong Kong/Auckland: 1st September 2014   Specialist pharmaceutical and medical technologies business, LINK Healthcare (‘LINK’) announced today that it has

LINK Healthcare receives marketing approval for EQUISIN® in South Africa  EQUISIN®, (exemestane) aromatase inhibitor is used in the treatment of breast cancer  Link’s brand is first-to-market generic to receive approval in South Africa  Link’s range of specialist oncology medicines is set to increase in the coming months Sydney/Pretoria/Singapore/Tokyo/Hong Kong/Auckland: 26th August 2014

LINK Healthcare receives generic approval for clindamycin hydrochloride 150 mg capsules  Latest addition to LINK’s growing generic range of specialist medicines  For the treatment of serious infections caused by susceptible bacteria Sydney/Pretoria/Singapore/Tokyo/Hong Kong/Auckland: 12th August 2014   Specialist pharmaceutical and medical technologies business, LINK Healthcare (‘LINK’) announced today that it has received Australian

LINK Healthcare Partners With Sigma Tau Group For Regional Distribution Rights To Rare Disease Therapeutics • Exclusive agreement to distribute  in selected countries of  Africa, Asia and Australasia:  Oncaspar® for the treatment of acute lymphoblastic leukemia; Adagen® for adenosine deaminase-severe combined immunodeficiency disease and Cystaran™ for ocular cystinosis • Territory rights expanded for Natulan™ for the treatment

LINK Healthcare PTE LTD and photonamic GmbH & Co. KG sign a licensing agreement for Alacare®, a new therapeutic for the treatment of actinic keratosis. This licensing agreement gives LINK exclusive rights to market Alacare® in Australia, New Zealand and South Africa. Alacare® is a photodynamic therapeutic in the form of a medicated patch for

Melbourne, Australia, June 20th 2013: Australian biotechnology company Avexa Limited [ASX:AVX] today announced that it has signed a binding term sheet with Link Healthcare Pte Ltd (LINK) for the development and commercialization of Avexa’s lead HIV drug apricitabine (ATC). “Avexa is delighted to expand our collaboration with Link” said Mr Iain Kirkwood, Chairman of Avexa,

Link Healthcare Obtains Extensive Regional Rights To  Secrelux From Sanochemia Sydney/Pretoria/Singapore/Tokyo/Auckland: 14 May 2013. Specialist pharmaceutical and medical technologies business, LINK Healthcare (‘LINK’) is pleased to announce that it has signed an agreement with Sanochemia Pharmazeutika AG for regional rights to Secrelux®, a pancreatic function diagnostic.LINK has been assigned the exclusive rights to Secrelux® for Australia, New

TOP